[HLIND] YoY TTM Result on 31-Dec-2021 [#2]

Stock
[HLIND] HONG LEONG INDUSTRIES BHD
Announcement Date
23-Feb-2022
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2022
Quarter
31-Dec-2021 [#2]
Profit Trend
QoQ- -10.94%
YoY- 20.37%
Quarter Report
Latest QR
Upcoming QR
HLIND's Result
HLIND's Financial Summary
View:
Show?
TTM Result
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Revenue 3,269,768 3,138,410 2,263,819 2,356,340 2,898,749 2,616,990 2,416,573 5.16%
PBT 569,951 495,270 361,340 337,397 501,958 464,447 244,937 15.10%
Tax -131,778 -115,321 -76,239 -83,556 -99,492 -66,868 -51,317 17.01%
NP 438,173 379,949 285,101 253,841 402,466 397,579 193,620 14.57%
-
NP to SH 325,336 291,919 215,360 178,918 311,751 326,575 134,457 15.85%
-
Tax Rate 23.12% 23.28% 21.10% 24.76% 19.82% 14.40% 20.95% -
Total Cost 2,831,595 2,758,461 1,978,718 2,102,499 2,496,283 2,219,411 2,222,953 4.11%
-
Net Worth 2,152,035 1,997,233 1,920,861 1,800,566 1,720,681 1,566,550 1,374,095 7.75%
Dividend
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Div 336,635 172,952 163,441 79,036 163,244 146,257 139,135 15.85%
Div Payout % 103.47% 59.25% 75.89% 44.17% 52.36% 44.79% 103.48% -
Equity
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Net Worth 2,152,035 1,997,233 1,920,861 1,800,566 1,720,681 1,566,550 1,374,095 7.75%
NOSH 327,903 327,903 327,903 327,903 327,903 327,903 327,905 -0.00%
Ratio Analysis
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
NP Margin 13.40% 12.11% 12.59% 10.77% 13.88% 15.19% 8.01% -
ROE 15.12% 14.62% 11.21% 9.94% 18.12% 20.85% 9.79% -
Per Share
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 1,039.26 997.83 720.09 749.87 923.19 833.60 780.85 4.87%
EPS 103.40 92.81 68.50 56.94 99.29 104.03 43.45 15.53%
DPS 107.00 55.00 52.00 25.17 52.00 47.00 45.00 15.52%
NAPS 6.84 6.35 6.11 5.73 5.48 4.99 4.44 7.46%
Adjusted Per Share Value based on latest NOSH - 327,903
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 1,038.90 997.16 719.28 748.68 921.02 831.49 767.82 5.16%
EPS 103.37 92.75 68.43 56.85 99.05 103.76 42.72 15.85%
DPS 106.96 54.95 51.93 25.11 51.87 46.47 44.21 15.85%
NAPS 6.8376 6.3458 6.1031 5.7209 5.4671 4.9774 4.3659 7.75%
Price Multiplier on Financial Quarter End Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 29/12/23 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 -
Price 9.21 9.20 9.18 8.89 10.42 8.50 9.69 -
P/RPS 0.89 0.92 1.27 1.19 1.13 1.02 1.24 -5.37%
P/EPS 8.91 9.91 13.40 15.61 10.49 8.17 22.30 -14.17%
EY 11.23 10.09 7.46 6.40 9.53 12.24 4.48 16.54%
DY 11.62 5.98 5.66 2.83 4.99 5.53 4.64 16.52%
P/NAPS 1.35 1.45 1.50 1.55 1.90 1.70 2.18 -7.67%
Price Multiplier on Announcement Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 21/02/24 16/02/23 23/02/22 26/02/21 26/02/20 18/02/19 05/02/18 -
Price 9.58 8.95 9.70 8.18 9.40 9.42 9.50 -
P/RPS 0.92 0.90 1.35 1.09 1.02 1.13 1.22 -4.59%
P/EPS 9.26 9.64 14.16 14.37 9.47 9.06 21.87 -13.33%
EY 10.79 10.37 7.06 6.96 10.56 11.04 4.57 15.38%
DY 11.17 6.15 5.36 3.08 5.53 4.99 4.74 15.34%
P/NAPS 1.40 1.41 1.59 1.43 1.72 1.89 2.14 -6.82%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment